Takeda plans to close its US headquarters in Deerfield, Illinois and move its functions to the Boston area. The move follows Takeda’s proposed $62-billion acquisition of Shire, announced in May 2018, which is scheduled to be completed in the first half of calendar year 2019. Shire, globally headquartered in Dublin, Ireland, has its US headquarters in Lexington, Massachusetts.

The work currently performed at the offices in Deerfield, Illinois will gradually shift to the Boston area after Takeda’s completion of its acquisition of Shire. In July 2018, Takeda received unconditional clearance from the US Federal Trade Commission for the company’s proposed $62-billion acquisition of Shire. Takeda is still awaiting approval from the European Union.

Takeda’s Deerfield headquarters has about 1,000 employees. Employees who are based at the Deerfield headquarters will be affected by the closure; however, some will receive relocation offers, according to the company. Takeda says a closure date hasn’t been set, but that employees should know their status within six months of the completion of the acquisition of Shire. Takeda, globally headquartered in Osaka, Japan, has approximately 5,000 employees in the US.

Source: Takeda Pharmaceutical Company